CollabRx, Medytox Reach Merger Agreement | GenomeWeb

NEW YORK (GenomeWeb) – CollabRx and Medytox today announced they have reached a definitive merger agreement. 

Under the terms of the deal, CollabRx shareholders will own a 10 percent stake in the combined company, of which it will operate as a wholly owned subsidiary. Medytox shareholders will own the remaining 90 percent. Further terms of the deal were not disclosed. 

The companies previously entered into a non-binding letter of intent to negotiate a merger.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.